28,818 Shares of Twist Bioscience Corporation $TWST Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. bought a new stake in Twist Bioscience Corporation (NASDAQ:TWST) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 28,818 shares of the company’s stock, valued at approximately $5,569,000.

Several other hedge funds also recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Twist Bioscience during the second quarter valued at about $600,191,000. William Blair Investment Management LLC acquired a new position in shares of Twist Bioscience in the 2nd quarter worth approximately $223,722,000. Bank of America Corp DE acquired a new position in shares of Twist Bioscience in the 2nd quarter worth approximately $94,922,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Twist Bioscience in the 1st quarter worth approximately $22,563,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Twist Bioscience during the 2nd quarter worth approximately $19,722,000.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 4,548 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $202.15, for a total transaction of $919,378.20. Following the completion of the sale, the chief executive officer owned 562,760 shares in the company, valued at $113,761,934. The trade was a 0.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Paula Green sold 10,088 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44. Following the completion of the transaction, the senior vice president directly owned 106,632 shares of the company’s stock, valued at $20,140,652.16. This trade represents a 8.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 601,920 shares of company stock worth $93,768,202 over the last three months. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $139.92 on Friday. The company has a market cap of $8.77 billion, a P/E ratio of -63.03 and a beta of 2.19. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The stock has a 50-day moving average of $149.89 and a two-hundred day moving average of $103.13. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $219.71.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The company had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. During the same period in the prior year, the company posted $0.33 EPS. The firm’s revenue was up 23.2% compared to the same quarter last year. As a group, analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. TD Cowen lifted their target price on shares of Twist Bioscience from $115.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Barclays boosted their target price on Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Guggenheim upped their price target on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. UBS Group assumed coverage on Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target for the company. Finally, Robert W. Baird raised their price target on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $143.67.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.